Gyeongnam Pharmaceutical Reports 39.3 Billion KRW in H1 Sales... "Record High Performance"

[Asia Economy Reporter Hyunseok Yoo] Gyeongnam Pharmaceutical announced on the 17th that it recorded sales of 39.3 billion KRW in the first half of 2021.

First-half sales increased by 16.8% compared to the previous year, reaching 39.377 billion KRW, achieving the highest performance ever, and operating profit rose 33.4% year-on-year to 2.134 billion KRW. Net profit for the period increased by 199.9% to 6.448 billion KRW.

Gyeongnam Pharmaceutical selected the girl group TWICE as the model for its flagship brand Lemona this year, expressing its intention to not only strengthen its position in the Japanese market but also accelerate its expansion into overseas markets such as Southeast Asia and North America.

They also strengthened their lineup by launching new products including 'VitaMed Lemona,' 'Skin Vitamin Lemona Pink,' and 'Lemona Pink Care.' They expanded their product range by releasing 'Linker Stick' for hydration and fatigue recovery.

In particular, on the 15th of last month, they completed a sales contract for Rapigen's 'BIOCREDIT COVID-19 Antigen Self-Test Kit,' which received official approval from the Ministry of Food and Drug Safety, and are expanding their business by supplying to local governments.

A company official said, "We achieved the highest performance ever in the first half of the year through various business expansions such as the Lemona lineup expansion," adding, "We will do our best to accelerate growth through diverse businesses in the second half of the year as well."

This content was produced with the assistance of AI translation services.